Compare Nasdaq Inc (NDAQ) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Tempus AI — how do they compare? Nasdaq Inc trades at $92.25 (market cap $51.39B), while Tempus AI trades at $70.05 (market cap $12.77B). The key difference: Nasdaq Inc is far larger — about 4× Tempus AI's market cap, and Nasdaq Inc pays a 1.26% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Tempus AI for 22 Days on average.
| NDAQ | TEM | |
|---|---|---|
Market Cap | $51.39B | $12.77B |
Volume | 3,123,797 | 8,980,490 |
Sector | Financials | Broad Market / Factor |
52-Week High | $100.98 | $99.28 |
52-Week Low | $76.85 | $41.55 |
Typical Hold Time | 125 Days | 22 Days |
Enterprise Value | $57.84B | $13.40B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $92.37, up 0.11% with a bearish technical signal despite beating earnings estimates for three consecutive quarters. The company shows strong fundamentals with 2025 revenue of $8.26B, net income margin of 22.52%, and consistent profitability. Recent news highlights Nasdaq's AI-powered Calypso platform expansion and index composition changes, while analyst consensus remains bullish with a $110.71 price target representing 20% upside potential.
NDAQ presents a compelling investment case with strong financial performance and analyst support, though technical indicators suggest near-term caution. The stock offers growth potential through technology innovation and market leadership, balanced by market volatility risks and competitive pressures in financial technology. Current valuation metrics (P/E 26.8, P/S 6.04) reflect premium pricing relative to historical averages.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
